The healthcare sector has been resilient through market drawdowns but also benefits from significant long-term growth drivers.
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
The Portfolio Construction and Strategy Team explain why investors should consider a dedicated allocation to healthcare.
Positive clinical trial data in 2022 could lead to record drug launches over the coming year.
Andy Acker discusses how pricing power, growing demand, and an improving outlook for biotech could bolster the sector heading into 2023.
Why health care could be well positioned to offer both defense against market volatility and opportunities for long-term growth.
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
Some areas of healthcare benefit from steady demand and the ability to pass on price increases – appealing qualities amid slowing economic growth.
The biopharmaceutical industry often moves to the beat of its own drummer, creating opportunities for diversification.
Healthcare technology companies are providing solutions to the rising demand for healthcare, but what are the implications for investors?
A breakthrough in anti-obesity medication could help millions of people struggling with excess weight and create a new growth opportunity for healthcare investors.
What are the opportunities in the healthcare sector in today’s uncertain financial markets?